The DataGov Lab, a European group of health data governance experts supported by ARIIS, announce the publication of its first report! The DataGov Lab started in 2017 from informal discussions between data governance representatives from different companies. In April 2019, the Datagov Lab was presented to the ARIIS Board of...En savoir plus
As part of the Strategic Contract for the Healthcare Industry and Health Technologies sectors and after more than two years of work between ARIIS and the National Cancer Institute, the Artificial Intelligence & Cancer project is one of the most significant achievements of ARIIS within the Artificial Intelligence & Health program. It aims to position France as an international leader in the field of cancer research and development and to modernize and differentiate the national data ecosystem to address needs that are currently unmet in cancer care.
Background & objectives
As the leading cause of death in Europe and soon worldwide, cancer remains a real challenge. The use of artificial intelligence in health data processing can be crucial in the research and development of new diagnostic and treatment strategies. To meet these challenges, the “Artificial Intelligence & Cancer” project is focused on five priorities:
- Build trust around health data, through greater transparency of means, objectives and expected results.
- Leading projects that address healthcare challenges, by carrying out Cancer Data Reuse Projects leading to innovative therapeutic and diagnostic solutions for the rarest and the most common cancers.
- Building an open environment for innovation, by accelerating the ability to access interoperable, consistent and complementary data for everyone.
- Leading a healthcare project consisting of decentralized projects, supported by industry companies and carried out at national, regional and even local level.
- Fostering dialogue with civil society, by committing to explaining cancer advances to the public and using pedagogy to communicate on the addressed issues: the role of data in innovation? what is artificial intelligence in oncology? what are its promises, developments and limits?
These priorities provide the basis for the operation and development of the project-leading “Filière Intelligence Artificielle et Cancer” Association. For more details, refer to the Association’s Charter of Common Values.
This project is led by the “Filière Intelligence Artificielle et Cancer” Association which was created on 3 August 2021. This Association has 11 founding members and is the result of a unique public-private partnership. It brings together:
- public actors represented by the National Cancer Institute and the Health Data Hub.
- private actors represented by ARIIS, France Biotech and 7 health industry companies (Amgen, AstraZeneca, Janssen, MSD, Novartis, Pfizer, Pierre Fabre).
The “Filière Intelligence Artificielle et Cancer” Association thus combines the strengths of every actor in their respective fields:
- ARIIS brings its federating vision to structure the health sector and its ability to create an effective space for dialogue, in particular between industry and public authorities;
- Health industry companies and biotechs bring their capacity for innovation, research and development;
- Public representatives bring their national and federating vision and guarantee that public interest and good data use are respected.
The creation of the Association is financially supported by the Public Investment Bank with €8.2 million and by the seven industry founding members of the project, each bringing one million euros over five years.
For more details on the missions and operation of the “Filière Intelligence Artificielle et Cancer” Association, refer to the Statutes of the Association.
With a very practical approach, the “Filière Intelligence Artificielle et Cancer” Association instructs and supports the implementation of Cancer Data Reuse Projects led by industry founding members, partners or customers. These projects are the expression of a variety of issues and challenges in the pharmaceutical and diagnostic sector and require innovative approaches to improve cancer knowledge and provide more precise medicine.
In accordance with the spirit of the health sector, the Association will also ensure overall consistency and coordination within the project. In this regard, all good practices and lessons learned from each project will be shared on the one hand to accelerate and build on success, and on the other hand to reduce failures by identifying obstacles.
The aim is to support 50 projects over 5 years.
LES DERNIÈRES ACTUALITÉS
ARIIS and France Biotech are joining forces for the “Biomarkers for Value” event on May 10, 2021! ARIIS and France Biotech, with the support of health competitiveness clusters, are organizing a day on biomarker issues on May 10, 2021 in order to raise biotechs’ awareness of the issues and challenges...En savoir plus
The taskforce “Use of real-world data in decision making” presents its recommendations! Set up as part of the Strategic Contract for the Healthcare Industry and Health Technologies sectors, which was signed on 04 February 2019, the taskforce “Use of real-world data in decision making” presents now its recommendations. Co-led by Laurie Lévy-Bachelot...En savoir plus